[Prognosis of lymphogranulomatosis (stage III B-IV) treated with drugs--results of a retrospective 10 year study].
With the help of survival curves of 91 patients with histologically ascertained lymphogranulomatosis a report on experiences concerning the prognostic importance of different factors is given. The examination is based on a retrospective analysis of a well documented number of patients who were chemotherapeutically treated from 1967--1976 in the medical outpatient department and the medical clinic of the Erfurt Academy of Medicine. We found on the basis of the retrospective study that the following factors deteriorate the prognosis: Clinical stage IV, presence of general symptoms, type poor in lymphocytes. Older age at making the diagnosis as well as male sex also reveal a worse prognosis as to the 3-year-survival rate than the comparative groups. Furthermore it was shown that the quality of remission after initial chemotherapy is of decisive prognostic valency. When cytostatic combination schemata were used for the induction of the remission the survival rates could be improved. The problems of the remission-keeping chemotherapy are entered.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D012075:Remission, Spontaneous; D012189:Retrospective Studies
D000970:Antineoplastic Agents
Zur Prognose der Lymphogranulomatose (Stadium III B-IV) unter Chemotherapie--Ergebnisse einer retrospektiven 10-Jahres-Studie.